Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1

Status

Completed 11Terminated 2Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 1Lymphoid 1

Conditions

Prostatic Neoplasms 3Leukemia 3Neoplasms 2Multiple Myeloma 2Lymphoma 2Leukemia, Myeloid, Acute 2Immunologic Deficiency Syndromes 2Graft vs Host Disease 2Fatigue 2Breast Neoplasms 2Brain Neoplasms 2Blast Crisis 2Waldenstrom Macroglobulinemia 1Stage IA Uterine Sarcoma 1Spinal Cord Neoplasms 1Spinal Cord Compression 1Sezary Syndrome 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleural Effusion, Malignant 1Paranasal Sinus Neoplasms 1Oligodendroglioma 1Neurologic Manifestations 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1

Interventions

Dexamethasone 112Bortezomib 61Lenalidomide 49Cyclophosphamide 49Calcium Dobesilate 43pomalidomide 32Melphalan 31fludarabine 25Filgrastim 25carfilzomib 22fludarabine phosphate 21daratumumab 20Granulocyte Colony-Stimulating Factor 16Whole-Body Irradiation 15Antilymphocyte Serum 15dexamethasone acetate 14Mycophenolic Acid 14Thalidomide 13Tacrolimus 13Cyclosporine 13Busulfan 13Peripheral Blood Stem Cell Transplantation 12ixazomib 11dexamethasone 21-phosphate 10auricularum 10pembrolizumab 9Radiotherapy 9Etoposide 9belantamab mafodotin 8Rituximab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Multiple Myeloma × Therapeutics × Clear all
NCT05655546 2025-08-08

ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals

Scripps Translational Science Institute

Phase NA Terminated
2,117 enrolled 6 charts
LymphoidOther hematologic neoplasmPlasma cell

COVID-19, Graft vs Host Disease, Immunologic Deficiency Syndromes, Leukemia, Lymphoma, Multiple Myeloma, Neoplasms, HIV Infections

NCT01892293 2019-01-10

CT Antigen TCR-Engineered T Cells for Myeloma

Adaptimmune

Phase 1/2 Terminated
6 enrolled 10 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡